Speakers

Anna Schwendeman is an Associate Professor at the Department of Pharmaceutical Sciences and a member of Biointerfaces Institute at the University of Michigan. Her research focus is on optimization high-density lipoprotein (HDL) nanoparticles as well as characterization of complex parenteral products (liposomes, microspheres, peptides and protein). In 2016, she co-founded a company EVOQ Therapeutics (www.evoqtherapeutics.com) focused on the use of HDL nanodiscs for delivery of personalized neoantigen cancer vaccines. Dr. Schwendeman received her BS from Moscow Institute of Physics and Technology and PhD in Pharmaceutics from The Ohio State University. Prior to starting her academic career in 2012, Dr. Schwendeman spent 12 years in pharmaceutical industry at Cerenis Therapeutics, Pfizer, and Esperion Therapeutics. She was involved in discovery and translation of HDL drugs to clinical trials including ETC-216, ETC-642, CER-001 and CER-522. She successfully submitted FDA INDs for seven different products including nanoparticles, liposome, recombinant proteins, peptides and small molecules. Her laboratory at the University of Michigan has expertise in development and analytical characterization of generic versions of Doxil®, AmBisome®, Exparel®, Lupron Depot®, Bydureon®, Forteo®, Byetta® as well as biosimars for infliximab, filgrastim, adalimumab, trastuzumab, bevacizumab, rituximab. Her laboratory is currently funded by multiple grants from NIH, FDA, AHA and pharmaceutical companies. She is co-director of FDA sponsored Center for Research in Complex Generics (http://www.complexgenerics.org ). Dr. Schwendeman is an Associate Editor for Nanomedicine NBM and Eur. J. Pharm and Biopharm.